This is the first article in a two-part series on tissue-agnostic drugs in cancer. The first part focuses on the emerging biomarkers researchers are studying and the second part focuses on the regulatory and financial considerations for drug developers.
Keytruda, Vitrakvi Approvals Spur Search for Other Targetable Biomarkers With Pan-Cancer Potential
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.